BINDING OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I (HIV-1) GP120 TO GALACTOSYLCERAMIDE (GALCER) - RELATIONSHIP TO THE V3 LOOP

被引:101
|
作者
COOK, DG
FANTINI, J
SPITALNIK, SL
GONZALEZSCARANO, F
机构
[1] UNIV PENN, MED CTR, DEPT NEUROL, PHILADELPHIA, PA 19104 USA
[2] UNIV PENN, MED CTR, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA
[3] FAC MED MARSEILLE, CNRS, URA 1455, F-13385 MARSEILLE, FRANCE
[4] UNIV PENN, MED CTR, DEPT LAB MED & PATHOL, PHILADELPHIA, PA 19104 USA
关键词
D O I
10.1006/viro.1994.1287
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The primary receptor for the human immunodeficiency virus (HIV) is the CD4 molecule. However, a large body of evidence has demonstrated that some cells that do not express the CD4 receptor can be infected by HIV-1 and HIV-2, indicating that an alternative mechanism of infection must exist for some cell types. Recently it was reported that antibodies against the glycosphingolipid, galactosylceramide (Gal beta 1-1'Cer; GalCer), blocked infection of several CD4 negative cell lines derived from the brain and colon. The hypothesis that GalCer might be involved in the process of HIV entry into these cells was further supported by the finding that recombinant gp120 bound GalCer with high affinity in a high performance thin layer chromatography (HPTLC) binding assay. We have examined the interactions between GalCer and gp120, and found that the oligosaccharides that constitute a large proportion of the molecular mass of this glycoprotein are not involved in binding to this glycolipid. Furthermore, using a panel of monoclonal and monospecific antibodies we have determined that gp120 binds GalCer, and the related molecule 3' sulfo galactosylceramide (sulfatide), at a site that is conformationally close to the its principal neutralizing domain (V3 loop) or at the V3 loop itself. (C) 1994 Academic Press, Inc.
引用
收藏
页码:206 / 214
页数:9
相关论文
共 50 条
  • [31] RELATIONSHIP BETWEEN THE V3 LOOP AND THE PHENOTYPES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) ISOLATES FROM CHILDREN PERINATALLY INFECTED WITH HIV-1
    MAMMANO, F
    SALVATORI, F
    OMETTO, L
    PANOZZO, M
    CHIECOBIANCHI, L
    DEROSSI, A
    JOURNAL OF VIROLOGY, 1995, 69 (01) : 82 - 92
  • [32] A PHASE I/IIA CLINICAL-STUDY WITH A CHIMERIC MOUSE-HUMAN MONOCLONAL-ANTIBODY TO THE V3 LOOP OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120
    GUNTHARD, HF
    GOWLAND, PL
    SCHUPBACH, J
    FUNG, MSC
    BONI, J
    LIOU, RS
    CHANG, NT
    GROB, P
    GRAEPEL, P
    BRAUN, DG
    LUTHY, R
    JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (06): : 1384 - 1393
  • [33] PRESENTATION OF NATIVE EPITOPES IN THE V1/V2 AND V3 REGIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 BY FUSION GLYCOPROTEINS CONTAINING ISOLATED GP120 DOMAINS
    KAYMAN, SC
    WU, ZW
    REVESZ, K
    CHEN, HC
    KOPELMAN, R
    PINTER, A
    JOURNAL OF VIROLOGY, 1994, 68 (01) : 400 - 410
  • [34] SYNTHETIC MULTIMERIC PEPTIDES DERIVED FROM THE PRINCIPAL NEUTRALIZATION DOMAIN (V3 LOOP) OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) GP120 BIND TO GALACTOSYLCERAMIDE AND BLOCK HIV-1 INFECTION IN A HUMAN CD4-NEGATIVE MUCOSAL EPITHELIAL-CELL LINE
    YAHI, N
    SABATIER, JM
    BAGHDIGUIAN, S
    GONZALEZSCARANO, F
    FANTINI, J
    JOURNAL OF VIROLOGY, 1995, 69 (01) : 320 - 325
  • [35] Structural analysis of the HIV-1 gp120 V3 loop: Application to the HIV-Haiti isolates
    Andrianov, Alexander M.
    Veresov, Valery G.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2007, 24 (06): : 597 - 608
  • [36] A BROADLY NEUTRALIZING MONOCLONAL-ANTIBODY THAT RECOGNIZES THE V3 REGION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GLYCOPROTEIN GP120
    OHNO, T
    TERADA, M
    YONEDA, Y
    SHEA, KW
    CHAMBERS, RF
    STROKA, DM
    NAKAMURA, M
    KUFE, DW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) : 10726 - 10729
  • [37] EFFECT OF MUTATIONS IN THE V3 LOOP OF HIV-1 GP120 ON INFECTIVITY AND SUSCEPTIBILITY TO PROTEOLYTIC CLEAVAGE
    SCHULZ, TF
    REEVES, JD
    HOAD, JG
    TAILOR, C
    STEPHENS, P
    CLEMENTS, G
    ORTLEPP, S
    PAGE, KA
    MOORE, JP
    WEISS, RA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (02) : 159 - 166
  • [38] THE HIV-1 V3 LOOP CONFORMATION AND ITS GP120 CONTEXT ARE BOTH IMPORTANT FOR NEUTRALIZATION
    ROBERTGUROFF, M
    MULDOON, R
    STERN, T
    ALDRICH, K
    LOUIE, A
    GROGG, D
    WHITESCHARF, M
    POTTS, B
    GALLO, RC
    REITZ, MS
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (06): : 679 - 679
  • [39] Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Zolla-Pazner, Susan
    Cohen, Sandra Sharpe
    Krachmarov, Chavdar
    Wang, Shixia
    Pinter, Abraham
    Lu, Shan
    VIROLOGY, 2008, 372 (02) : 233 - 246
  • [40] Prediction of HIV-1 coreceptor usage based on structural descriptors of the gp120 V3 loop
    Sander, O.
    Sing, T.
    Sommer, I.
    Low, A. J.
    Cheung, P. K.
    Harrigan, P. R.
    Lengauer, T.
    Domingues, F. S.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S16 - S16